Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences' stock has experienced significant movement in the past six months. As of April 2, 2026, the share price was $22.96, a 234.21% increase from April 4, 2025. Positive clinical data for casdatifan, the full year and fourth quarter 2025 earnings report, and the advancement of pipeline programs have impacted the stock price. The company reported positive data for casdatifan in late-line kidney cancer, demonstrating a median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45%. The company reported $1.0 billion in cash, cash equivalents, and marketable securities at year-end 2025, providing a cash runway until at least the second half of 2028. Ongoing enrollment in the Phase 3 PEAK-1 study for casdatifan and the planned initiation of another Phase 3 study for casdatifan by the end of 2026, along with the completion of quemliclustat's Phase 3 enrollment, indicate significant progress in the company's clinical pipeline.

As a clinical-stage biopharmaceutical company, Arcus Biosciences' products are not yet commercialized, so there is no direct demand seasonality. The company's revenue is primarily derived from collaborations and license agreements, rather than product sales. The company's stock performance and investor interest can be influenced by the timing of clinical trial readouts, regulatory milestones, and financial reporting.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing differentiated molecules and combination therapies for cancer, inflammatory, and autoimmune diseases. Founded in 2015, the company operates in the biotechnology and medical research sector, with a focus on immuno-oncology. The company's pipeline includes investigational products like Domvanalimab, Casdatifan, Etrumadenant, Quemliclustat, Zimberelimab, AB308, AB521, AB598 and AB801. The company leverages biologic pathways to create innovative treatments, emphasizing discovery, accelerated development, and strategic partnerships with companies like Gilead Sciences and AstraZeneca.

Arcus Biosciences, Inc. is headquartered in Hayward, California, United States. The company is described as a global biopharmaceutical company, and its Phase 3 PEAK-1 study for casdatifan is enrolling globally.

Arcus Biosciences' brand reputation appears to be largely positive, driven by promising clinical trial results and strategic partnerships. The company is recognized as a clinical-stage immuno-oncology company focused on developing best-in-class molecules and combination therapies for cancer. Strong clinical data for casdatifan, strategic partnerships with major pharmaceutical companies like Gilead Sciences and AstraZeneca, and financial stability have positively affected its reputation.

Arcus Biosciences, Inc. is primarily owned by institutional investors and its largest strategic partner, Gilead Sciences, Inc., which holds approximately 33% of the company's equity. Institutional investors collectively own around 83.49% of the company's shares. Major institutional owners and shareholders include Gilead Sciences Inc., BlackRock, Inc., Vanguard Group Inc., and others. Insider ownership stands at approximately 5.52%, with the company's co-founders, Terry Rosen, Ph.D. (CEO), and Juan Jaen, Ph.D. (President and Head of R&D), being significant individual stakeholders.